BridgeBio Pharma SG&A Expenses 2018-2023 | BBIO
BridgeBio Pharma annual/quarterly sg&a expenses history and growth rate from 2018 to 2023. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
- BridgeBio Pharma sg&a expenses for the quarter ending December 31, 2023 were $0.048B, a 49.34% increase year-over-year.
- BridgeBio Pharma sg&a expenses for the twelve months ending December 31, 2023 were $0.151B, a 5.17% increase year-over-year.
- BridgeBio Pharma annual sg&a expenses for 2023 were $0.151B, a 5.17% increase from 2022.
- BridgeBio Pharma annual sg&a expenses for 2022 were $0.143B, a 25.5% decline from 2021.
- BridgeBio Pharma annual sg&a expenses for 2021 were $0.192B, a 31.94% increase from 2020.
BridgeBio Pharma Annual SG&A Expenses
(Millions of US $) |
| 2023 |
$151 |
| 2022 |
$143 |
| 2021 |
$192 |
| 2020 |
$146 |
| 2019 |
$94 |
| 2018 |
$44 |
| 2017 |
$13 |
BridgeBio Pharma Quarterly SG&A Expenses
(Millions of US $) |
| 2023-12-31 |
$48 |
| 2023-09-30 |
$36 |
| 2023-06-30 |
$36 |
| 2023-03-31 |
$31 |
| 2022-12-31 |
$32 |
| 2022-09-30 |
$31 |
| 2022-06-30 |
$36 |
| 2022-03-31 |
$44 |
| 2021-12-31 |
$55 |
| 2021-09-30 |
$46 |
| 2021-06-30 |
$46 |
| 2021-03-31 |
$45 |
| 2020-12-31 |
$37 |
| 2020-09-30 |
$36 |
| 2020-06-30 |
$38 |
| 2020-03-31 |
$34 |
| 2019-12-31 |
$35 |
| 2019-09-30 |
$23 |
| 2019-06-30 |
$17 |
| 2019-03-31 |
$19 |
| 2018-12-31 |
|
| 2018-09-30 |
$10 |
| 2017-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$5.200B |
$0.009B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
